🧾 What This Document Is

This is TAO Synergies Inc.'s annual report (Form 10-K) for the fiscal year ended December 31, 2025. Think of it as a comprehensive school report card, but for a public company. It’s required by the SEC and tells investors everything about the business, its finances, and the major risks it faces. The big story here isn't just the numbers—it's about a company that has completely transformed its business model.

🏢 What The Company Does — A Radical Pivot

👉 In simple terms, TAO Synergies used to be a biotech company trying to develop Alzheimer's drugs. Now, it’s primarily a company that buys and stakes a cryptocurrency called TAO to generate yield.

The company was formerly called Synaptogenix and focused on a drug candidate called Bryostatin-1. However, after a strategic review in late 2024, it pivoted dramatically. In June 2025, it rebranded to TAO Synergies and launched a "cryptocurrency treasury strategy." Its main goal is to use its cash to buy TAO, the native token of the Bittensor blockchain (a decentralized AI network), and then "stake" those tokens to earn rewards. They view their TAO holdings as a long-term investment.

💰 Financial Highlights — Cash is King, Revenue is Not

The financial picture reflects a company in transition, burning cash while it builds its new crypto treasury.

Revenue: The company reported $0 in revenue for 2025. It has no operating business generating sales yet.
Cash Position: As of December 31, 2025, the company had $15.8 million in cash and cash equivalents.
Net Loss: It reported a net loss of $25.3 million for the year, up from a loss of $14.2 million in 2024. This loss is primarily from operating expenses as it builds its new strategy and winds down its old operations.
Market Value: As of June 30, 2025, the market value of its stock held by non-affiliates was $19.4 million. As of March 2026, there were about 7.47 million shares outstanding.

👉 Why it matters: The company is currently a pre-revenue venture. Its value isn't in sales today, but in the cryptocurrency assets it accumulates and the potential appreciation of those assets. The heavy losses show it's spending money to fund this transformation.

🚀 Key Moves — The Great Crypto Shift

The most important actions in 2025 were all about executing the pivot:

Name Change: On June 26, 2025, it officially changed its name from Synaptogenix, Inc. to TAO Synergies Inc.
Treasury Strategy Launch: It announced a strategy to allocate "excess cash" (cash beyond 1.5-2 years of operating needs) to purchase TAO. As of September 2025, ~88% of its treasury holdings were already in TAO.
New Team: It engaged prominent crypto figures James Altucher and Joseph Jacks as consultants, paying them with warrants to buy company stock.
Infrastructure Setup: It established critical partnerships:
- Custodian: BitGo Bank and Trust, N.A. to securely hold its TAO.
- Prime Broker: BitGo Prime LLC to facilitate trading.
- Staking Validators: tao5 and Yuma Validator, LLC to stake its TAO and earn rewards.

📦 Financial Position — Heavy on Assets, Light on Equity

The balance sheet shows a company funding its new venture.

Total Assets: $31.3 million, dominated by cash and the TAO cryptocurrency it holds.
Total Liabilities: $11.1 million, which includes various payables and accrued expenses from its operations.
Stockholders' Equity: $20.2 million. This is the residual value for shareholders after subtracting liabilities from assets.

👉 Why it matters: The company has a solid cash cushion but is unprofitable. Its success hinges entirely on the value of its TAO holdings and its ability to generate yield from staking, not on selling products.

💸 Cash Flow Story — Investing in the Future

Cash flow tells you where money is actually moving.

Operating Activities: Used $23.1 million in cash. This is the money burned to keep the lights on, pay consultants, and fund the wind-down of the old biotech business.
Investing Activities: Provided $5.9 million. This is unusual and likely came from selling certain investments or assets from its prior life.
Financing Activities: Provided $28.6 million. This is the lifeline—the company raised cash by issuing new stock and warrants to investors to fund its crypto strategy.

👉 Why it matters: The company is surviving by selling new shares (diluting existing owners) to fund its operating losses and its big bet on TAO cryptocurrency.

🧪 The Legacy Business — A Dormant Pipeline

The report details the company's original biotech work, which is now largely inactive.

Alzheimer's Disease: Its lead drug candidate, Bryostatin-1, failed to meet primary goals in multiple Phase 2 clinical trials. The development program is effectively on hold.
Other Diseases: It had exploration agreements for Fragile X syndrome (with Nemours) and Multiple Sclerosis (with Cleveland Clinic). The Cleveland Clinic agreement was terminated in December 2024 to cut costs. The Fragile X program is under an FDA clinical hold.
Intellectual Property: It holds exclusive licenses to patents related to Bryostatin-1 from entities like Cognitive Research Enterprises, Inc. and Mt. Sinai.

👉 Why it matters: This is now a legacy, non-core asset. The company's future is not tied to these drug development efforts, though the licenses remain on its books.

🔮 What's Next — Building a TAO Treasury

The company's future strategy is clear:

Accumulate TAO: Continue using excess cash and potentially raise more capital (via debt or equity) to buy more TAO. It has no specific target amount.
Stake for Yield: Stake all acquired TAO through validators to earn rewards. It does not currently hedge its price exposure.
Explore Subnets: May eventually participate in more complex "subnet" activities on Bittensor to enhance yield, likely with expert partners.
Media Arm: It launched "The TAO Daily," a media platform focused on the Bittensor ecosystem, hosted by its consultants.

⚖️ Big Picture — Strengths & Risks

👍 Potential Strengths:

Focused Bet: A pure-play, concentrated investment in a specific crypto asset (TAO) tied to the growing field of decentralized AI.
Experienced Advisors: Engagement of well-known crypto operators like Altucher and Jacks.
Institutional-Grade Setup: Use of regulated custodians (BitGo) and established validators.

⚠️ Major Risks:

Extreme Volatility: The price of TAO can swing wildly, potentially wiping out the value of the treasury.
Execution & Strategy Risk: The entire business model is new and unproven. There is no guarantee staking will be profitable or that the strategy will work.
Regulatory Uncertainty: Cryptocurrency regulations are evolving and could negatively impact staking or TAO's status.
Dilution: The company will likely need to issue more shares to fund operations and purchases, reducing existing shareholders' ownership percentage.
Liquidity Risk: While TAO has a market, large sales could be difficult without impacting the price.

🧠 The Analogy

Imagine a struggling bakery that owns a valuable, old oven (its biotech patents). One day, the owner decides the future isn't in baking, but in gold mining. They sell some pastries (legacy assets) and take out a big loan (issue stock) to buy a gold mine (TAO). They hire experienced miners (Altucher, Jacks) and now spend all their time digging for gold (staking), hoping the price of gold goes up. The bakery oven sits unused in the corner. Their entire success depends on the gold mine, not the bakery.

📇 Key Contacts & People

Company: TAO Synergies Inc.
Address: 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036
Phone: 973-242-0005
Auditor: Stephano Slack LLC (Wayne, PA)
Key Consultants Mentioned:
- James Altucher (via Z-List Media, Inc.)
- Joseph Jacks
Key Service Providers:
- BitGo Bank and Trust, N.A. (Custodian)
- BitGo Prime LLC (Prime Broker)
- Yuma Validator, LLC (Staking Services)

🧩 Final Takeaway

TAO Synergies has executed a complete metamorphosis from a failed biopharmaceutical company to a corporate treasury vehicle whose primary asset is the TAO cryptocurrency. Its value now depends almost entirely on the performance of the Bittensor network and the price of TAO, making it a high-risk, high-potential-reward bet on decentralized AI.

TAO Synergies Inc. — 10-K Filing